Most patients with moderate to severe plaque psoriasis who received treatment with brodalumab experienced long-term rates of skin clearance at 120 weeks, according to extension results of AMAGINE-2.
“The increased likelihood of achieving complete skin clearance associated with brodalumab may allow improvement of patient quality of life relative to other biologics associated with a lesser rate of achieving complete skin clearance,” Luis Puig, MD, director of the dermatology department at Hospital de la Santa Creu I Sant Pau in Barcelona, Spain, and colleagues wrote.
Click here to read the full article.
Credit: www.healio.com